Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated reports developments for a global medical technology business that supplies hospitals and healthcare providers with devices used in anesthesia, emergency medicine, interventional cardiology and radiology, surgery, vascular access and urology. Its established brands include Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift and Weck.
Recurring Teleflex news covers quarterly financial results, outlook updates, revenue trends by global product category, portfolio realignment and integration of acquired vascular intervention assets. Company updates also include governance and leadership changes, board committee matters, capital allocation actions, shareholder communications and operational initiatives such as integrated demand and supply planning.
Teleflex will host an Analyst & Investor Day on May 20, 2022, in New York City. The event features presentations from CEO Liam Kelly and the leadership team, starting at 10:00 a.m. ET. Key agenda items include discussions on durable growth, growth drivers, and financial objectives for 2023-2025. Following the presentations, there will be live breakout sessions. The webcast will be available on the company’s website after the event.
Teleflex (NYSE: TFX) announced a quarterly cash dividend of $0.34 per share, payable on June 15, 2022, to shareholders of record by the close of business on May 16, 2022. As a global provider of medical technologies, Teleflex focuses on innovations to improve healthcare outcomes across various fields, including vascular access and anesthesia. This dividend reflects the company's commitment to returning value to shareholders while continuing its mission to meet clinical needs effectively.
Teleflex (NYSE: TFX) reported Q1 2022 revenues of $641.7 million, showing a 1.2% year-over-year increase. GAAP diluted EPS rose to $1.63 from $1.58 in the prior year. The company reiterated its 2022 GAAP revenue growth guidance of 2.3% to 3.8% and adjusted diluted EPS guidance of $13.70 to $14.30. Segment performance varied, with the Americas growing 0.7%, EMEA declining 3.1%, and Asia increasing by 8.6%. Teleflex acknowledged ongoing inflation and supply chain challenges but remains optimistic about its growth potential.
Teleflex Incorporated (NYSE: TFX) will feature its Chairman and CEO, Liam Kelly, at the Bank of America Securities 2022 Healthcare Conference. The event takes place on May 10, 2022, at 11:20 a.m. (PT) in Las Vegas. A live audio webcast of the presentation will be accessible on the investor section of the Teleflex website.
Teleflex Incorporated (NYSE:TFX) announced a conference call scheduled for 8:00 a.m. Eastern Time on April 28, 2022, to discuss its first quarter 2022 results and provide an operational update. Interested participants can register through a specified link, and a replay of the call will be available starting at 11:00 a.m. on the same day. Teleflex focuses on innovative medical technologies across various fields, including vascular access and anesthesia, aimed at improving health outcomes.
Teleflex Incorporated (NYSE: TFX) has launched the UroLift System in Japan, addressing benign prostatic hyperplasia (BPH). This minimally invasive treatment offers quick symptom relief and allows patients to resume normal activities while preserving sexual function. With prior reimbursement approval from the Central Social Insurance Medical Council of Japan, the system is now commercially available. Teleflex aims to make the UroLift System the standard of care for BPH globally, marking a significant step in its overseas expansion strategy.
Teleflex's CFO, Thomas Powell, will present at the KeyBanc Life Sciences & MedTech Investor Forum on March 23, 2022, at 9:45 a.m. (ET). Investors can access a live audio webcast of the presentation on the Teleflex website. The company is a global provider of medical technologies, focusing on enhancing health and quality of life through innovative solutions in various medical fields. Teleflex is recognized for its trusted brands, including Arrow®, QuikClot®, and LMA®.
Teleflex Incorporated (NYSE: TFX) will feature its Chairman, President, and CEO, Liam Kelly, at the 43rd Annual Raymond James Institutional Investors Conference. The event will be held on March 8, 2022, at 9:15 a.m. ET in Orlando, FL. A live audio webcast and accompanying slide presentation will be accessible on Teleflex's investor website. As a leading provider of medical technologies, Teleflex aims to improve health and quality of life through innovative solutions across various fields such as vascular access, anesthesia, and emergency medicine.
Teleflex (NYSE: TFX) has declared a quarterly cash dividend of $0.34 per share, payable on March 15, 2022, to shareholders recorded by March 7, 2022. This dividend reflects the company's commitment to providing value to its investors while operating in the medical technology sector. Teleflex focuses on diverse medical solutions aimed at improving health outcomes globally, with a strong emphasis on innovation and addressing unmet clinical needs.
Teleflex reported fourth quarter revenues of $761.9 million, reflecting a 7.1% year-over-year increase. The GAAP diluted EPS was $2.69, up from $1.62, while adjusted diluted EPS rose to $3.60, marking a 10.8% increase. For 2022, the company expects GAAP revenue growth of 2.3% to 3.8% and adjusted EPS between $13.70 and $14.30. The respiratory divestiture is projected to affect growth, contributing a 1.6% headwind. Teleflex emphasized its strategy for sustainable growth and enhancement of margins amid operational challenges.